Tomasz Iwanowski
Research Subjects
Tomasz Iwanowski has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Małgorzata Sokołowska-Wojdyło
Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-214 Gdańsk, Poland
2 shared publications Piotr Szlązak
Dermedica, Gdansk, Poland
2 shared publicationsAlicja Rustowska
Medpharma, Warsaw, Poland
1 shared publicationBerenika Olszewska
Department of Dermatology, Venerology and Allergology, Medical University of Gdańsk, Gdańsk, Poland
1 shared publication- Karol Kołkowski
Dermatological Students Scientific Association, Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland
1 shared publication Małgorzata Sokołowska-Wojdyło
Department of Dermatology, Venerology and Allergology, Medical University of Gdańsk, Gdańsk, Poland
1 shared publication
Latest Publications
- Open Access
- 5 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9749
Etiopathogenesis and Emerging Methods for Treatment of Vitiligo
Vitiligo is an acquired chronic depigmenting disorder of skin. It is mostly asymptomatic and characterized by amelanotic macules and patches that affects 0.5% to 2% of the world’s population. The etiology of vitiligo has not been clearly elucidated and multiple theories have been proposed regarding the causes of the disorder. Among the most prevalent theories, the genetic predisposition, oxidative stress theory, promotion of cellular stress and pathologic influence of lymphocytes T have been highlighted. As a result of increases in in-depth knowledge concerning the pathogenetic processes in vitiligo, we review the most recent information concerning its etiopathogenesis and treatment methods including topical and oral Janus kinase inhibitors, prostaglandins and their analogues, namely afamelanotide, Wnt/β-catenin-signaling agonists and cell-based therapies. Topical ruxolitinib has been registered for vitiligo treatment, whereas other agents as oral ritlecitinib, afamelanotide and latanoprost have been studied in ongoing clinical trials. New highly effective therapeutic strategies may be developed thanks to molecular and genetic studies.
- 5 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9749
Open AccessEtiopathogenesis and Emerging Methods for Treatment of Vitiligo
Vitiligo is an acquired chronic depigmenting disorder of skin. It is mostly asymptomatic and characterized by amelanotic macules and patches that affects 0.5% to 2% of the world’s population. The etiology of vitiligo has not been clearly elucidated and multiple theories have been proposed regarding the causes of the disorder. Among the most prevalent theories, the genetic predisposition, oxidative stress theory, promotion of cellular stress and pathologic influence of lymphocytes T have been highlighted. As a result of increases in in-depth knowledge concerning the pathogenetic processes in vitiligo, we review the most recent information concerning its etiopathogenesis and treatment methods including topical and oral Janus kinase inhibitors, prostaglandins and their analogues, namely afamelanotide, Wnt/β-catenin-signaling agonists and cell-based therapies. Topical ruxolitinib has been registered for vitiligo treatment, whereas other agents as oral ritlecitinib, afamelanotide and latanoprost have been studied in ongoing clinical trials. New highly effective therapeutic strategies may be developed thanks to molecular and genetic studies.
- Open Access
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 38 (4) , 636-643
Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Polish
Introduction Vitiligo is an acquired chronic depigmenting disorder of the skin, predominantly asymptomatic. Although vitiligo does not cause direct physical impairment, it is commonly believed that it can produce an important psychosocial burden. Aim: To translate, cross-culturally adapt and...
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 38 (4) , 636-643
Open AccessTranslation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Polish
Introduction Vitiligo is an acquired chronic depigmenting disorder of the skin, predominantly asymptomatic. Although vitiligo does not cause direct physical impairment, it is commonly believed that it can produce an important psychosocial burden. Aim: To translate, cross-culturally adapt and...
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 35 (6) , 592-598
Efficacy of suction blister epidermal grafting with concomitant phototherapy in vitiligo treatment
Introduction : There are many surgical methods for vitiligo treatment that have been used for over 30 years. Suction blister epidermal grafting (SBEG) is considered one of the simplest and most effective of them. Aim : To determine how effective suction blister grafts with concomitant...
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 35 (6) , 592-598
Open AccessEfficacy of suction blister epidermal grafting with concomitant phototherapy in vitiligo treatment
Introduction : There are many surgical methods for vitiligo treatment that have been used for over 30 years. Suction blister epidermal grafting (SBEG) is considered one of the simplest and most effective of them. Aim : To determine how effective suction blister grafts with concomitant...